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Abstract We report a case of primary malignant mela-
noma (MM) of the stomach. The patient, a 73-year-old
man, was referred to our hospital for investigation of an
elevated lesion in the stomach, detected by gastroscopy. On
admission, physical examinations and laboratory data were
unremarkable. Gastroscopy revealed a pigmented, elevated
tumor, approximately 2 cm in diameter, in the posterior
wall of the stomach. A biopsy was taken, which resulted in
a diagnosis of MM, based on the presence of melanin in
tumor cells. F-18 ﬂuorodeoxyglucose positron emission
tomography showed no accumulation of tracer except for
the tumor in the stomach, indicating that it was a primary
MM of the stomach. The patient underwent distal gas-
trectomy, but died of recurrence 1 year later. Very few
cases of primary MM of the stomach have been reported.
Thus, we report this case, followed by a review of the
literature.
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Introduction
Occasionally, ectopic neoplasms arise in the gastrointesti-
nal (GI) tract [1]. Malignant melanoma (MM) usually
arises from typical sites where there are melanocytes:
namely, the skin, eyes, meninges, and anal region. While it
is found occasionally in the GI tract, the vast majority of GI
melanomas are metastases from a cutaneous primary tumor
[2]. In fact, clinical GI tract involvement secondary to
cutaneous melanoma has been reported in up to 4% of
living patients and up to 60% at autopsy [3, 4]. Conversely,
primary MM of the GI tract, particularly in the stomach, is
extremely rare, although sporadic cases have been reported
[5–14]. We present another case of primary MM of the
stomach, which to our knowledge, is the ﬁrst documented
case of a primary MM of the stomach, from Japan.
Case report
A 73-year-old man was referred to our hospital after gas-
troscopy had shown an elevated lesion in the posterior wall
of the stomach. On admission, he appeared in good health,
withoutperipheraladenopathy,andlaboratorydata,including
serum lactate dehydrogenase (LDH), were all within nor-
mal limits. Gastroscopy showed a pigmented, elevated
lesion, approximately 2 cm in diameter, in the posterior
wall of the stomach (Fig. 1). A biopsy was performed and
histologic examination revealed sheet-like malignant cells
with large nuclei and eosinophilic cytoplasms containing
dark brown pigment (Fig. 2a). Immunohistochemically, the
tumor cells were positive for S-100 proteins (Fig. 2b)
and HMB-45 antibodies (Fig. 2c), and negative for pan-
cytokeratin antibodies (AE1/AE3) and leukocyte common
antigen. Based on these ﬁndings, we diagnosed MM.
Ophthalmologic, dermatologic, and oral examinations were
negative, as were computed tomography of the chest and
anoscopy. Furthermore, F-18 ﬂuorodeoxyglucose positron
emission tomography (FDG-PET) showed no accumulation
of tracer, except in the tumor of the stomach (Fig. 3).
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primary MM of the stomach without metastases. The
resected specimen contained a brown-pigmented fungiform
tumor, 2 cm in diameter, in the posterior wall of the
stomach (Fig. 4). Postoperative histological and immuno-
histochemical examinations conﬁrmed the diagnosis.
Tumor cells were spreading through the submucosal layer
of the stomach, but the resection margins were clear of
tumor. Six of 27 resected lymph nodes were positive for
metastases. The patient was discharged from our hospital
after an uneventful recovery, and was followed up at
another hospital. He was readmitted to our hospital
9 months later with abdominal pain, general fatigue, and
anorexia. A subcutaneous tumor in his back was resected
and pathological examination revealed a metastasis of MM
(Fig. 5). Computed tomography showed ascites and pleural
effusions, but cytological examinations of the ﬂuid were
negative. He became extremely cachectic and died
approximately 2 months later; 1 year after the gastrectomy.
Discussion
Primary MM of the stomach is extremely rare. Since nor-
mal stomach epithelium lacks melanocytes, the cell of
origin remains obscure, although possible etiologies of
primary MM have been suggested. For example, ectopic
migration of melanocyte precursors or differentiation of the
APUD cells (amine precursor uptake and decarboxylation
cells) to melanocytes has been suggested as a possible
mechanism of the development of MM [8, 15, 16]. Criteria
for the diagnosis of primary MM include the absence of
other primary site melanomas and no history of the
Fig. 1 Endoscopic examination showed a pigmented elevated lesion
in the posterior wall of the stomach
Fig. 2 a Histology showed sheet-like malignant cells with large
nuclei and eosinophilic cytoplasms containing dark brown pigment.
b Tumor cells were positive for HMB-45 antibody. c Tumor cells
were also positive for S-100 protein. a H&E, 9400; b and c immu-
nohistochemistry, 9200
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123removal of a melanoma or atypical melanocytic lesion
from the skin or other organs [5, 17]. It is recognized that
spontaneous regression of primary melanoma occasionally
occurs [5, 7, 18, 19]. Moreover, metastatic melanoma of
the GI tract is found in up to 60% of autopsies of patients
who have died with primary cutaneous melanoma [3, 4].
Therefore, it is important to be aware of the danger of
misinterpreting metastasis to the gastric wall. Our patient
had no remarkable history and FDG-PET showed no
accumulation of tracer, other than the tumor in the stom-
ach. Therefore, occult primary MM in another site seems
highly unlikely. A deﬁnitive diagnosis of MM was made by
immunohistological examination of harvested tissues.
Since melanocytes are very sensitive to S-100 proteins and
HMB-45 antibodies, immunohistochemical staining with
those pigments is important to conﬁrm the presence of
melanocytes in a tumor [5, 7, 20]. Immunohistochemical
examination of the tumor from our patient revealed a
positive reaction with S-100 proteins and HMB-45 anti-
bodies, which led us to assume a primary MM of the
stomach. MMs that arise in mucosal surfaces appear to be
more aggressive and associated with a worser prognosis
than cutaneous MMs. This poorer prognosis may be related
to late diagnosis, an inherently more aggressive behavior of
mucosal MM, or earlier dissemination because of the rich
lymphaticandvascularsupplyofGItractmucosa[5,7,8,10].
It has been reported that the median overall survival
associated with primary MM of the GI tract is 17 months,
whereas that associated with primary MM of the stomach is
only 5 months [21]. Although there are no widely accepted
treatment protocols for primary MM of the GI tract, sur-
gical resection is the only identiﬁable treatment modality
for which independent predictive prognostic values have
been demonstrated [21]. It was also reported that age
[70 years, stage (localized or distant), tumor location, and
lymph node involvement are independently predictive of
the prognosis of patients with primary MM of the GI tract
[21]. The factors of age, tumor location, and lymph node
involvement were applicable to our patient. On the other
hand, some serum substances are known tumor markers of
cutaneous MM. Although there are few markers that are
useful for early detection of MM [22], some markers
Fig. 3 FDG-PET showed accumulation of tracer in the gastric tumor
(arrow). No accumulation was observed in any other site
Fig. 4 Surgical specimen from the distal gastrectomy. a There was a tumor in the posterior wall of the stomach. b The tumor was
2.0 9 1.9 9 0.9 cm in size
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123such as LDH, S-100B protein, neuron-speciﬁc enolase, and
5-S-cysteinyldopa are recognized as signiﬁcant prognostic
factors [23, 24]. We examined only serum LDH levels,
which were within normal limits in our patient. To our
knowledge, there are no reports on tumor markers of pri-
mary MM of the GI tract. Therefore, clinical studies are
required to identify markers that could be used for the early
detection or prognosis of MM of the GI tract. A number of
randomized controlled trials (RCTs) have been conducted
to evaluate the efﬁcacy of chemotherapy, non-speciﬁc
immune stimulants such as bacillus Calmette–Guerin,
Corynebacterium parvum, levamisole, or combinations of
these agents with dacarbazine chemotherapy [25], but none
of these therapies is recognized as efﬁcient. However, the
use of interferon alpha (INF-a) in the adjuvant setting has
been approved recently for prolonging disease-free survival
in patients with high-risk cutaneous MM [26]. Although
RCTs have not shown their signiﬁcant effect on overall
survival, a meta-analysis of the results of 14 RCTs indi-
cated that IFN-a adjuvant treatment achieved signiﬁcant
improvement in both the disease-free survival and the
overall survival of patients with high-risk cutaneous MM
[27]. It is possible that the prognosis of our patient could
have been improved if we had given him adjuvant therapy
after gastrectomy. Future studies are required to assess
whether adjuvant therapies using agents such as INF-a
can prolong the survival of patients with MM of the GI
tract.
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